Business
Everest Medicines to Host Virtual Nephrology-Focused KOL Event on June 30, 2025
Event titled “A Conversation on the Latest Results from the Ongoing Phase 1b/2a Clinical Trial of EVER001, a Next-Generation Covalent Reversible BTK Inhibitor for the Treatment of Primary Membranous Nephropathy (pMN)” SHANGHAI, June 26, 2025 (GLOBE NEWSWIRE) -- Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it will host
About this update from Everest Medicines Ltd.
[{"type":"image","alt":"Everest Medicines","displaySize":"","headline":null,"caption":"Everest Medicines","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":196,"url":"https://media.zenfs.com/en/globenewswire.com/e0f7ff6f0fa6ce558a982afa44bc0984"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xaXwScgvYm8K56BQcEMrJA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e0f7ff6f0fa6ce558a982afa44bc0984","width":300,"height":196}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Event titled “A Conversation on the Latest Results from the Ongoing Phase 1b/2a Clinical Trial of EVER001, a Next-Generation Covalent Reversible BTK Inhibitor for the Treatment of Primary Membranous Nephropathy (pMN)”","length":217,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":217,"olType":false},{"type":"text","content":"SHANGHAI, June 26, 2025 (GLOBE NEWSWIRE) -- Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it will host a virtual nephrology-focused key opinion leader (KOL) event on Monday, June 30, 2025 at 8:00 AM ET. For English speakers, please click here to register. For individuals preferring instant Chinese translation, please click here.","length":509,"tagName":"p"},{"type":"text","content":"The event will feature:","length":23,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Richard Lafayette, MD - Professor of Medicine, Stanford University","length":66,"tagName":"p"}]},{"val":[{"type":"text","content":"Ian Woo - President and Chief Financial Officer at Everest Medicines","length":68,"tagName":"p"}]},{"val":[{"type":"text","content":"Sandra Zeng - Chief Medical Officer at Everest Medicines","length":56,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":190,"olType":false},{"type":"text","content":"The speakers will present an overview of pMN and the current treatment landscape in the U.S. and China, followed by a discussion of the latest data cut from the EVER001 trial as of March 21, 2025.","length":196,"tagName":"p"},{"type":"text","content":"Everest recently presented an update on this study at the European Renal Association and reported posit...